Pharmaceuticals

With a new CFO known for billion-dollar deals and a promising gout drug, Crystalys Therapeutics is gearing up for a pivotal run at the global market.

A new, self-administered RNA therapy for hereditary angioedema gains EU approval, promising fewer attacks and greater freedom for thousands of patients.

BioAge Labs is developing an oral drug for diabetic macular edema, a breakthrough that could end the need for frequent, invasive eye injections for millions.

A new partnership promises up to 22% savings for employers by integrating deep pharmacy expertise, tackling one of healthcare's most complex challenges.

A new partnership between Vida Health and RxSaveCard offers employers a way to subsidize pricey weight-loss drugs outside of traditional insurance plans.

A clinical trial for D-Serine begins in Norway, testing a novel approach that could finally slow or halt the progression of Parkinson's disease.

A new AI-driven platform from CAS aims to democratize complex IP research, making high-stakes patent analysis accessible to entire organizations.

Novavax lands a major partnership with Pfizer for its Matrix-M adjuvant, a deal that provides a crucial financial boost and validates its pivot to a tech provider.

Ascletis Pharma unveils ASC37, a next-gen, once-monthly obesity drug claiming superior potency and convenience, challenging giants like Eli Lilly.

A new partnership aims to simplify access to custom-compounded drugs for weight loss and HRT, blending digital tech with specialized pharmacy services.

With booming exports and robust government backing, Italy is making a strategic play to become a global life sciences powerhouse. Here's what's driving the momentum.

Australian biopharma Immuron reports strong global sales for its travel supplement and launches a new IBS product, navigating industry mergers and digital trends.

Veteran drug discoverer Dr. Adam Davenport joins as CSO, bringing expertise in cutting-edge modalities to accelerate client pipelines in a competitive market.

Advicenne's novel therapy for distal Renal Tubular Acidosis is under FDA review, potentially bringing the first approved treatment to thousands in the U.S.

At a major San Francisco summit, Chinese biotechs unveiled breakthrough heart and cancer drugs, signaling a strategic shift from manufacturing to global innovation.

Hong Kong-based Cellyan Biotechnology has 180 days to rescue its Nasdaq listing after its stock price fell below the $1.00 minimum requirement.

Genmab's antibody drug epcoritamab is the first of its kind to slow cancer progression in a Phase 3 trial for R/R DLBCL, offering a new path for patients.

Crosswalk Therapeutics secures a key grant to develop a therapy targeting the debilitating skeletal disease in Morquio A, a challenge current treatments can't solve.

A new North Carolina facility will use advanced Blow-Fill-Seal tech to produce essential medicines, aiming to fix supply chains and reduce US reliance on imports.

Profusa launches its Lumee system for research, aiming to capture a piece of the $47B CRO market and revolutionize drug development with real-time data.